Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer

AH Hansma; H.J. Broxterman; I. van der Horst; Y. Yuana; E. Boven; G. Giaccone; H.M. Pinedo; K. Hoekman

doi:https://doi.org/10.1093/annonc/mdi318

Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer

AH Hansma, H.J. Broxterman, I. van der Horst, Y. Yuana, E. Boven, G. Giaccone, H.M. Pinedo, K. Hoekman

VU University medical center

Research output: Contribution to journal › Article › Academic › peer-review

63 Citations (Scopus)

Original language	English
Pages (from-to)	1695-1701
Journal	Annals of Oncology
Volume	16
Issue number	10
DOIs	https://doi.org/10.1093/annonc/mdi318
Publication status	Published - 2005

Access to Document

https://doi.org/10.1093/annonc/mdi318

Cite this

Hansma, AH., Broxterman, H. J., van der Horst, I., Yuana, Y., Boven, E., Giaccone, G., Pinedo, H. M., & Hoekman, K. (2005). Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Annals of Oncology, 16(10), 1695-1701. https://doi.org/10.1093/annonc/mdi318

@article{3ecffce99c2441e5ad3aaf088ebf3de5,

title = "Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer",

author = "AH Hansma and H.J. Broxterman and {van der Horst}, I. and Y. Yuana and E. Boven and G. Giaccone and H.M. Pinedo and K. Hoekman",

year = "2005",

doi = "https://doi.org/10.1093/annonc/mdi318",

language = "English",

volume = "16",

pages = "1695--1701",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "10",

}

Hansma, AH, Broxterman, HJ, van der Horst, I, Yuana, Y, Boven, E, Giaccone, G, Pinedo, HM & Hoekman, K 2005, 'Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer', Annals of Oncology, vol. 16, no. 10, pp. 1695-1701. https://doi.org/10.1093/annonc/mdi318

Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. / Hansma, AH; Broxterman, H.J.; van der Horst, I. et al.
In: Annals of Oncology, Vol. 16, No. 10, 2005, p. 1695-1701.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer

AU - Hansma, AH

AU - Broxterman, H.J.

AU - van der Horst, I.

AU - Yuana, Y.

AU - Boven, E.

AU - Giaccone, G.

AU - Pinedo, H.M.

AU - Hoekman, K.

PY - 2005

Y1 - 2005

U2 - https://doi.org/10.1093/annonc/mdi318

DO - https://doi.org/10.1093/annonc/mdi318

M3 - Article

SN - 0923-7534

VL - 16

SP - 1695

EP - 1701

JO - Annals of Oncology

JF - Annals of Oncology

IS - 10

ER -